Akum Pharma Asked to Submit Safety Data for Alzheimer's Drug Combo In Elderly Indian Patients

Written By :  Dr. Divya Colin
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-08-05 12:01 GMT   |   Update On 2025-08-05 12:01 GMT
Advertisement

New Delhi: In a recent regulatory review, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) asked the pharma major Akum Pharmaceutical to submit supportive data with respect to safety aspects for the Donepezil Hydrochloride IP 10mg/10 mg/10 mg/10mg + Memantine Hydrochloride IP (ER) 7 mg/14 mg/21 mg/28mg hard gelatin capsule in elderly/geriatric population in Indian patients.

This came after the firm presented the proposal before the committee.

Donepezil is in a class of medications called cholinesterase inhibitors. It improves mental function (such as memory, attention, the ability to interact with others, speak, think clearly, and perform regular daily activities) by increasing the amount of a certain naturally occurring substance in the brain.

Donepezil is a medication that treats symptoms of Alzheimer’s disease like memory loss and confusion. This medication works by improving your attention, memory and ability to engage in your daily activities. It isn’t a cure for Alzheimer’s disease or dementia.

Advertisement

At the recent SEC meeting for Neurology and Psychiatry held on 16th July 2025, the expert panel reviewed the proposal presented by the Akum Pharmaceutical.

After detailed deliberation, the committee opined that firm did not present any supportive data with respect to safety aspects for the proposed FDC in elderly/geriatric population in Indian patients.

"Accordingly, the firm should submit above data for further review by the committee," the expert panel noted.

Also Read: Zydus Told To Conduct Phase III Trial in India for Lurbinectedin Injection, BE Study Waived

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News